BRISBANE, Calif., March 18 InterMune, Inc.(Nasdaq: ITMN) issued the following statement regarding today's indictment ofa former employee in connection with the promotional activities forActimmune(R) (interferon gamma-1b) during a period that ended in June of 2003.
"Today's indictment concerns conduct by a former employee who left thecompany more than four years ago.
"In 2006, InterMune settled all government claims related to that conduct,without criminal sanctions against the company. At the time, the governmentacknowledged that InterMune fully cooperated with its investigation and hadinstituted numerous and comprehensive compliance changes before theinvestigation even began. Today's government action does not affect theCompany's settlement in any way.
"In today's action, the government is bringing charges against a formeremployee, not against InterMune, its current employees or its Directors.
"Since 2004, InterMune has been a transformed company with a newmanagement team, a rigorous compliance program and a promising pipelinefocused on serious pulmonary and hepatic diseases.
"We have taken great strides to put this matter behind us and have focusedour resources on what we believe is a promising future for our Company and ourshareholders."
The individual charged today was Scott Harkonen, formerly President, ChiefExecutive Officer and a Director of InterMune.
InterMune is a biotechnology company focused on the research, developmentand commercialization of innovative therapies in pulmonology and hepatology.InterMune has a research and development portfolio addressing idiopathicpulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. Thepulmonology portfolio includes the Phase 3 program, CAPACITY, which isevaluating pirfenidone for the treatment of patients with IPF and a researchprogram focused on small molecules for pulmonary disease. The hepatologyportfolio includes the HCV protease inhibitor compound ITMN-191 (referred toas R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitorresearch program, and a research program evaluating a new target inhepatology. For additional information about InterMune and its R&D pipeline,please visit http://www.intermune.com.
This news release contains forward-looking statements within the meaningof section 21E of the Securities Exchange Act of 1934, as amended, thatreflect InterMune's judgment and involve risks and uncertainties as of thedate of this release. All forward-looking statements and other informationincluded in this press release are based on information available to InterMuneas of the date hereof, and InterMune assumes no obligation to update any suchforward-looking statements or information. InterMune's actual results coulddiffer materially from those described in InterMune's forward-lookingstatements.
Factors that could cause or contribute to such differences include, butare not limited to, those discussed in detail under the heading "Risk Factors"in InterMune's most recent annual report on Form 10-K filed with the SEC onMarch 14, 2008 (the "Form 10-K") and other periodic reports filed with theSEC, including the following: (i) risks related to the long, expensive anduncertain clinical development and regulatory process, including having nounexpected safety, toxicology, clinical or other issues or delays inanticipated timing of the regulatory approval process; (ii) risks related tofailure to achieve the clinical trial results required to commercialize ourproduct candidates; and (iii) risks related to timely patient enrollment andretention in clinical trials. The risks and other factors discussed aboveshould be considered only in connection with the fully discussed risks andother factors discussed in detail in the Form 10-K and InterMune's otherperiodic r